<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2323812187-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2323812187-430x241.jpg"/>
                                    
                                    <figcaption>The FDA has approved a label change to Pfizer’s contraceptive injection, Depo Provera, which will warn prescribers and patients of the increased risk of meningioma associated with the drug’s use. Image credit: ShU studio via ShutterStock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>The US Food and Drug Administration (FDA) has approved a label change to Pfizer’s injectable contraceptive, Depo-Provera (medroxyprogesterone acetate), which will warn users of their increased risk of meningioma.</p>



<p>The FDA’s crackdown on Depo-Provera comes amid a highly publicised legal battle between Pfizer and more than 2,000 women, who are currently suing the New York-based pharma after they developed meningiomas they believe are caused by exposure to the contraceptive.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - GSK-2256098 in Meningioma </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Pritumumab in Meningioma </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Depo-Provera contains progestin, a synthetic form of the sex hormone progesterone. While it has been on the contraceptive market since the early 1990s, a recent study published in the <em>British Medical Journal</em> has uncovered the heightened risk of intracranial meningioma associated with the jab’s prolonged use.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>A December 2023 National Health Statistics Report estimates that nearly 24.5% of all sexually experienced women in the US have used Depo-Provera at some point between 2015 and 2019.</p>



<p>Meningiomas are tumours that grow in the protective membranes that coat the brain and spinal cord. Patients with meningiomas commonly experience headaches, seizures, weakness and numbness. Though they are typically benign, they can have a significant impact on a patient’s quality of life (QoL). In some cases, they are also life-threatening.</p>



<p>The FDA’s call to enforce a label warning for Depo-Provera marks a potential turn in the agency’s stance on the contraceptive, as it previously rejected Pfizer’s label update application in 2024.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<h2 id="h-fda-clampdown-could-spell-legal-trouble-for-pfizer">FDA clampdown could spell legal trouble for Pfizer</h2>



<p>Throughout the legal battle between Pfizer and the 2,000-plus plaintiffs, claims against the big pharma have largely centred around its failure to warn doctors and patients of the risk of meningioma associated with Depo-Provera’s use.</p>



<p>Pfizer has previously argued in court that the FDA had prohibited it from including a label warning on Depo-Provera, thus prompting the company to request the dismissal of such lawsuits.</p><div id="slot-two"></div>



<p>However, Ben Martin, founder of the drug and medical device litigation group, Ben Martin Law Group, told <em>Pharmaceutical Technology</em> that this defence may no longer hold up in court. </p>



<p>Martin said: “This ‘impossibility’ pre-emption argument should now fail given that a warning was not only possible but that the FDA is now requiring such a warning.</p>



<p>“Pfizer has known for decades that there may be an association between the use of Depo-Provera and the development of meningiomas.”</p>



<p>In his eyes, the New York-based pharma “could and should have performed studies exploring this link”, which would have uncovered the greater risk of developing meningioma with the use of Depo-Provera versus not using it.</p>



<p>Bryan Aylstock  of  Aylstock Witkin Kreis &amp; Overholtz, Christopher Seeger of Seeger Weiss, and Ellen Relkin of Weitz &amp; Luxenberg, co-lead counsel in the Depo-Provera Products Liability Litigation echoed this sentiment, adding that Pfizer’s misconduct has caused “lasting neurological damage, vision loss and death” in women who developed brain tumours caused by Depo-Provera.</p>



<p>“We applaud the FDA in finally requiring this label change to better inform and protect women,” they concluded.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
Discover the Impact

             </div>

<p>The FDA has approved a label change for Pfizer's contraceptive injection, Depo-Provera, to warn of the increased risk of meningioma. This decision follows over 2,000 lawsuits from women claiming the contraceptive caused their meningiomas. The FDA's previous rejection of Pfizer's label update application in 2024 is now overturned. Legal experts suggest Pfizer's defense may weaken as the FDA now mandates the warning.</p>

- The FDA has approved a label change for Pfizer's Depo-Provera to warn about the increased risk of meningioma for users.  
- This decision comes amid ongoing lawsuits from over 2,000 women claiming the contraceptive caused their tumors, highlighting Pfizer's alleged failure to adequately warn about these risks.  
- The approval of the warning marks a shift in the FDA's stance, potentially influencing the legal outcomes for Pfizer in these cases.

FDA approves meningioma label warning on Pfizer’s contraceptive injection